Granules India Attains ANDA Approval for Metoprolol Succinate ER Tablets, Expanding its Pharmaceutical Portfolio”
Granules India Attains ANDA Approval for Metoprolol Succinate ER Tablets, Expanding its Pharmaceutical Portfolio
Granules India Limited that the (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg. It is bioequivalent to the reference listed drug product (RLD), Toprol-XL Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Toprol Acquisition LLC.
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
Granules now has a total of 57 ANDA approvals from US FDA (55 final approvals and 2 tentative approvals).
The current annual U.S. market for Metoprolol Succinate ER Tablets is approximately $321Million, according to MAT Mar 2023, IQVIA/IMS Health.
Enchanting Charms of Uttarakhand: Journey into the Land of Majestic Mountains, Serene Hill Stations
